Amarin's (NAS: AMRN) new triglyceride-lowering drug, Vascepa, could have major advantages for patients over its main competitor -- GlaxoSmithKline's (NYS: GSK) Lovaza -- since one of Lovaza's components has been associated with increasing LDL cholesterol, more commonly referred to as "bad" cholesterol. That could translate to major profits for Amarin should Vascepa reach the market, but the stock has stumbled recently due to delays in getting the NCE, or New Chemical Entity, status from the Food and Drug Administration. That has been tricky to get, since the main component of Vascepa is in fact part of Lovaza. In this video, Motley Fool health care analyst Max Macaluso sheds some light on why the FDA hasn't decided on Vascepa's status yet and what investors need to know going forward.
The biotech space can make or break investors ovnight, and while Amarin might not disappear into thin air, Vascepa's FDA status and the decisions the company makes in commercializing it will be key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article Science Amarin Investors Need to Know originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.